BAX: GAMMAGARD S/D

Baxter recently released the results of one of their current FDA studies that are showing promising results with new product development. Although the new GAMMAGARD S/D and GAMMAGARD liquid will have to go through more lengthy testing before being approved for use with Alzheimer's patients, there seems to be light at the end of the tunnel. If approved this treatment will become an instant cash cow. According to the study the results are astounding and are better than they expected. Look for this stock to stay strong for a long period of time.